Cambridge Clinical Vision Laboratory (CCVL)

The CCVL is a dedicated facility for vision research embedded within the NIHR Cambridge Clinical Research Facility in a strategic location next to the Early Phase Trials Unit.

The CCVL is part of a major drive by the NIHR Cambridge BRC to fast-track advanced gene therapy and cell-based therapies for ocular and neurodegenerative diseases. We also support early-phase experimental trials exploring novel chemotherapeutic and immunomodulatory agents for cancer and various autoimmune diseases.

The CCVL is available to assist and support your studies, including grant applications. Please contact us to discuss your ideas and requirements further.

Cambridge Enterprise

We help transform your ideas into commercial opportunities attractive to organisations that can bring them to market and support formation of new companies and social enterprises.

We also manage the commercial relationship and negotiation of relevant agreements. Our remit extends to supporting the development of intellectual property arising from NIHR Cambridge BRC activities and collaborations between the University of Cambridge and the NHS; if you are either a CUH NHS Trust employee, or a University employee supported by the NIHR Cambridge BRC, and want to discuss how to commercialise your technology, we have the experience and expertise to support you.

If you are ready to disclose your idea confidentially, then please complete our Idea Disclosure form.

If you would like to ask us a question, please email CBRCIPSupport@enterprise.cam.ac.uk, and someone from the team will get in touch with you.

The Evelyn Perinatal Imaging Centre

Its internationally-competitive programme of research brings together clinicians, engineers and physicists to develop new technologies to study the causes, detection and diagnosis of brain injury in newborns.

Located in the Rosie maternity hospital, close to the neonatal intensive care unit (NICU), postnatal wards and birthing suite, the centre houses a physics laboratory, clinical 1.5T MRI scanner and infant scanning room with dedicated MRI-compatible incubator, making it safer and easier to transfer sick and preterm infants.

The centre enables researchers and clinicians to study and care for critically-ill babies in their first hours of life, in an infant-friendly and safe environment. Enhanced clinical care means babies’ outcomes have the best chance of improving and also facilitates new lines of neuroprotective treatments.

Through its ties with the University’s Department of Paediatrics and with NIHR Cambridge BRC support, the Evelyn Perinatal Imaging Centre is playing a key role in developing neonatal neurocritical care (‘Neuro-NICU’), to improve the quality of care for newborn infants with congenital and acquired brain injury. The centre is also closely involved with The Next Generation Children project, which is undertaking whole genome sequencing on infants with altered neurology and seizures.

The centre has enabled a number of successful commercial, industrial and academic collaborations in Cambridge, London and Europe, including the development of a 3D optical imaging system and state-of-the-art EEG monitoring systems. Together these systems provide a unique multimodal imaging facility to study brain development in the newborn, identify those at risk of long-term brain injury and better understand how babies respond to different treatments.

To find out how this facility can help your research or to enquire about opportunities for collaboration, please contact Centre Director Professor Topun Austin. For more information on the centre and current research projects, visit https://neolabresearch.com.

Clinical Trials Pharmacy

The team also have growing experience with Advanced Therapy IMPs and work closely with Cambridge Cellular Therapy Laboratory to provide pharmaceutical governance for studies involving cellular treatments.

Pharmacy clinical trial support is an integral part of the research process and has a vital role to play in safeguarding participants, healthcare professionals and the Trust by ensuring IMPs and other study medications are appropriate for use and are procured, handled, stored and used safely and correctly in line with regulatory requirements.  A dedicated Clinical Trials Dispensary is on site and pharmacy aseptic dispensing facilities are also available.

For Trust-sponsored Clinical Trials of IMPs (CTIMPs), pharmacy are involved from the outset of a project and work closely with Cambridge Clinical Trials Unit to advise on costings for grant applications, protocol design and review of the overall trial application in relation to medication, including manufacturing and participating site aspects.  Pharmacy will also advise on non-CTIMP research as required.

NIHR Cambridge BRC Cell Phenotyping Hub

The Hub’s mission is to deliver advanced scientific technologies for supporting the excellence in research of a partnership between the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust.

The Hub provides state-of-the-art resources and cost-effective high quality scientific, educational and technological expertise and services across the wide range of cytomics and immune phenotyping. These services fall mainly into three major areas: research service, clinical services and technology services. They include but are not limited to fluorescence-activated and magnetic cell isolation and purification, single cell analysis, confocal imaging, sample preparation (laser capture microdissection and blood processing) and comprehensive phenotyping from sample to data. The Hub is equipped with state-of-the-art equipment including high-speed cell sorters, bench-top analysers and high content/high throughput equipment.

A further function of the Hub is to collect and to disseminate the unique technological and scientific expertise crucial for promoting and supporting patient-based basic research and for translating basic biological findings into clinical practice. The Hub drives technological innovations and applies technical and instrumental advances to expand the portfolio of services and fulfill the emerging research needs. Our group consists of research and support scientists and technologists with a long history record of research and development and with commensurate levels of scientific and technical expertise. Through our collaborative Research and Development service we foster and fortify collaborations that result in many major publications across nearly all Departments of the Clinical School and BRC themes.

The main Hub laboratories are located in the Jeffrey Cheah Biomedical Centre and on Levels 5 and 6 of the Addenbrooke’s main hospital block. Additional outlet is being established in the laboratories of HLRI. For access to the Hub services, all new clients and prospective collaborators are invited to attend a Hub induction to discuss their research needs and to customise service provision (contact via e-mail below).

SMCL Next Generation Sequencing (NGS) Hub

The Stratified Medicine Core Laboratory (SMCL) NGS Hub is involved in world class sequencing research partnerships with clients both within the University of Cambridge and the Cambridge University Hospital NHS Foundation Trust, along with further external Academic and Commercial organisations.

The SMCL NGS Hub aims to provide a comprehensive and expert Next Generation Sequencing service to the academic, clinical & commercial community, with the distinctive mission of providing a clinical translational service.

The SMCL NGS Hub is hosted by the Department of Medical Genetics of the University of Cambridge and, uniquely, housed in the Medical Genetics Laboratories of the East Midlands and East of England NHS Genomic Laboratory Hub (East GLH), allowing us to offer researchers access to clinical grade next generation sequencing services.

What can SMCL offer to the academic, clinical and commercial communities?

  • SMCL offers researchers access to clinical grade next generation sequencing; a range of platforms to suit all budgets and coverage requirements at short turnaround times.
  • SMCL can provide a complete ‘end to end’ service with a fully flexible approach, encompassing nucleic acid extraction and sample QC, full library preparation and sequencing and bioinformatics analysis or support (or individual parts of this pathway).
  • SMCL also offers advice on experimental and project design, and can tailor services (e.g., bespoke NGS assays) to specific project needs.
  • SMCL’s typical services include:
    • Extraction services
    • Library Prep
    • Clinical Grade Whole Genome Sequencing
    • Clinical Grade Whole Exome Sequencing
    • Clinical Grade Targeted Sequencing
    • RNA-SEQ
    • Epigenetic analysis (targeted methylation assays, genome wide methylation profiling, RRBS).
  • SMCL equipment
    • Illumina sequencers
    • Illumina cBot
    • Agilent Tapestation
    • QIAGEN QIAsymphony
    • Beckman Coulter Biomek FXP
    • Covaris E220 Focused Ultrasonicator

Please visit SMCL website for further details about the facility’s services and equipment.

For quotes and general enquiries, please contact SMCL by email.

PET/CT Merck

The MRC clinical infrastructure funding has provided exciting new opportunities with the upgraded 3T and new 7T MRI, PET-MR and a second clinical hyperpolariser. In addition, an upgraded and extended GMP PET radiopharmaceutical unit with an on-site cyclotron and state-of-the-art radiochemistry systems with the capability of producing a large range of short-lived and longer-lived PET radiotracers. These installations will particularly facilitate and enhance experimental therapeutic trials in dementia, oncology, cardiovascular medicine and within other themes in the Cambridge BRC.

NIHR BioResource for Translational Research in Common and Rare Diseases

The NIHR BioResource have a panel of around 200,000 volunteers nationally, both with and without health conditions, who are willing to be approached to participate in research studies investigating the links between genes, the environment, health and disease. Volunteers donate their DNA via a blood or saliva sample and complete a health questionnaire to match them to specific research studies.

The BioResource Centre Cambridge is one of the local sites run at the NIHR Cambridge BRC.

Cambridge Clinical Research Centre (CCRC)

The NIHR/Wellcome Trust Clinical Research Facility (also a cross-cutting theme in the NIHR Cambridge BRC), is a 24/7 inpatient unit with a Metabolic Research Area containing measurement technologies for energy balance and body composition allied to metabolic magnetic resonance spectroscopy in the Wolfson Brain Imaging Centre. This CRF has dedicated facilities to accommodate children. 

The Clinical Investigation Ward (CIW) operates on a day case basis, undertaking later-phase clinical trials.

With a five floor expansion of campus clinical research capacity, facilities include:

Level 2, Interventional Investigation Unit: Facilities to undertake research endoscopies; cell therapy and minor procedures.

Level 3, Early Phase Trials Unit: Dedicated facilities for early phase studies including first-in-human trials.

Level 4 and 6, Wellcome-MRC Metabolic Translational Research Facility: Conducts metabolic studies linked to research programmes funded by the Wellcome Trust-MRC Institute of Metabolic Science (IMS). With dedicated space and equipment for studying patients and volunteers in a naturalistic setting  

Level 5, Clinical Research Facility: A 24/7 unit accommodating research in diverse specialties in adult patients and volunteers.

  • To contact the CCRC call: 01223 254800.

hIPSC Core Facility

Derivation of hIPSC lines for disease modelling.

The core facility has successfully generated high-quality iPSCs from more than 500 patients. Upon request, the core facility can derive hIPSCs from dermal fibroblast cultures or peripheral blood mononuclear cells (PBMCs), using non-integrative reprogramming techniques. The resulting pluripotent stem cells can then be differentiated into cell types affected by disease for basic studies and drug screening applications. Derivation submission form

Genome editing using CRISPR-Cas9 technology.

CRISPR-Cas9 has emerged as a powerful tool to generate hIPSC lines with knockout for specific genes and to correct disease-causing mutations, thereby creating isogenic cell lines for disease modelling. The core facility has successfully applied this technology to generate knock out and knock in hIPSCs. We can assist on any stage of the process including designing and cloning of the constructs, transfection and genotyping.

Training for IPSC derivation, IPSC culture and genome editing.

The BRC hIPSC core facility provides hands-on training for derivation, characterization, differentiation and genome editing of hIPSCs.

 Available resources:

Future activities of the hIPSCs core facility will also include the derivation of primary organoid culture from adult organs including liver and gut.

Cambridge Clinical Trials Unit

The CCTU works with researchers from Cambridge University Health Partners (CUHP) to conduct the highest quality clinical research, addressing important questions related to human health and disease. Major areas within our portfolio include: oncology, cardiovascular disease, infection and immunity, paediatrics, neurology, neurosciences and trauma, imaging, surgery and peri-operative care.

We strive to deliver world class clinical trials ranging from national to international, single to multi-centre, CTIMPS, non-CTIMPs and medical device trials. The CCTU supports all trial stages, from study design, costing grant proposals, developing protocols, obtaining necessary approvals, delivery and quality control, to data management, final analysis and dissemination.

The CCTU is part of the NIHR UKCRC Registered CTU Network, and receives NIHR CTU Support Funding to develop and conduct NIHR trials. The CCTU is also a member of the NCRI Cancer CTU. We are a founding member of the International Clinical Trials Centre Network, which aims to improve clinical research by fostering collaborations worldwide.

Find out more details of their studies and Covid-19 research.

Core Biochemical Assay Laboratory (CBAL)

The majority of the 300+ different tests offered by CBAL use immunoassay technology. CBAL performs MesoScale Discovery, Luminex Magpix, DELFIA and ELISA assays plus those available on the Siemens Dimension EXL, Diasorin Liaison XL and Randox Daytona+ Autoanalysers.

CBAL has a good track record of developing novel high quality assays for biomarkers that are not readily available from commercial vendors.

The laboratory is located on Level 4 of the Addenbrooke’s Laboratory block. It currently has CPA-accreditation for its two most requested ‘clinical’ assays (insulin & c-peptide); other assays are unaccredited but performed to the highest standard. CBAL is staffed by up to seven highly experienced NHS Biomedical Scientists, funded by the NIHR Cambridge Biomedical Research Centre. All staff have received GCP training and participate in CPD schemes.

Brain Bank

The donation of post-mortem brain tissue for research is of fundamental importance to further understanding of the causes of these disorders and to develop more effective diagnostic tools and treatments for these conditions.

NIHR BRC-MRC BioRepository

The NIHR BRC-MRC BioRepository is a modern laboratory based in the centre of Addenbrooke’s Hospital, providing research support for studies and trials on the Cambridge Biomedical Campus.  It has expertise in supporting small research projects through to large multi-site national studies where it receives, processes, stores, retrieves blood and other research material.  The facility has some of the most advanced automated systems for retrieving and arraying biological material for biomarker applications.  In addition to this, it has efficient and cost effective systems for extracting DNA, and can provide a full DNA QC and quantification service.  All the material that is processed in the laboratory is entered into a Laboratory Information Management System (LIMS); this provides a full electronic chain of custody for samples.  The facility has monitored Ultra Low Temperature Freezers that can be used for short-term storage and a team of five expert staff to provide dedicated research support.

Gut Reaction

Gut Reaction was funded for an initial 3-year period by Health Data Research UK (HDR UK), through the UK Research and Innovation (UKRI) Industrial Strategy Challenge Fund (ISCF), to facilitate research into IBD by bringing together datasets from different sources.

From September 2022, Gut Reaction will continue as part of the NIHR Bioresource. Working with their partners, collaborators and the IBD community, they will continue to support research that makes a difference to those living with IBD. You can browse or apply to access available datasets by visiting their data pages and learn more about how they work with the IBD community on their patient pages.

If you would like to get in touch with the Gut Reaction team, please email them on gutreaction@bioresource.nihr.ac.uk